Poxel SA

Poxel SA is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for serious chronic diseases with metabolic pathophysiology. Headquartered in Lyon, France, the company focuses its research and development efforts primarily on non-alcoholic steatohepatitis (NASH) and various rare metabolic disorders.

The company's pipeline includes several drug candidates. TWYMEEG® (Imeglimin), a first-in-class product targeting mitochondrial dysfunction, received approval in 2021 and is currently marketed for the treatment of type 2 diabetes in Japan by its partner, Sumitomo Pharma, generating royalties and sales-based payments for Poxel. PXL065, a deuterium-stabilized R-pioglitazone, is being developed for NASH and has successfully met its primary endpoint in a streamlined Phase 2 trial.

In recent developments, Poxel announced the sale of its drug candidate PXL770, a direct AMPK activator previously focused on rare diseases like adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD), to Scynexis for up to $196 million in March 2026. This strategic move allows Poxel to concentrate its resources on TWYMEEG® and PXL065. Nicolas Trouche serves as the CEO, leading the company in its pursuit of new partnerships and value creation within the biopharmaceutical landscape.